DENVER--(BUSINESS WIRE)--Colorado BioScience Association (CBSA) announces the appointment of Scott Larson as its new chairman of the board of directors. Larson, Senior Vice President of Legal and General Counsel for the global medical device innovator, Lakewood-based Terumo BCT, will lead CBSA for a two-year term. Larson replaces outgoing chair Mark Spiecker, who will continue to serve on the CBSA board and executive committee through 2017.
Joining Larson and Spiecker in executive committee positions are:
Vice Chairman: Ginny Orndorff, Director, CID4
Treasurer:
Jim Wilson, Partner, E&Y
Secretary:
Alan Rudolph, Ph.D., Vice President for Research, Colorado
State University
Membership Chair: Dustin Whistler, Forte
Commercial Real Estate
Policy Chair: Dan Wittenberg, Snell
& Wilmer
Scott Larson, Chairman of the Board for CBSA, said:
“The
Colorado BioScience Association supports our fast-growing sector by
focusing efforts on the themes that matter most to our members,
including increasing access to capital, highlighting their success
stories, and connecting talent within Colorado biosciences. I’m proud to
work with our board to directly contribute to the vitality of our
bioscience sector.”
The 30-person CBSA board of directors is comprised of representatives from the state’s biotechnology, medical device, diagnostic, pharmaceutical, ag bio, digital health, healthcare and research organizations.
Newly Appointed Board Members:
Frank Segrave, CEO, Silvergate
Pharmaceuticals
Christopher Banas, CEO, Bio2
Medical
Chris McDonald, Vice President of Global
Biologics – Colorado, AstraZeneca
Shelley
Zelin, Vice President Human Resources, Allosource
April Giles, President and CEO of CBSA said:
“Our newest
board members, all from commercial companies, represent a shift in our
state’s bioscience sector. While Colorado is known for a thriving
start-up community, several of our companies are moving from the
emerging or mid-stage into the manufacturing stage. We’re pleased to
welcome leaders from Silvergate Pharmaceuticals, Bio2Medical,
AstraZeneca and Allosource to the Colorado Bioscience Association Board
of Directors.”
Board members commit to a three-year term and work in partnership with CBSA staff to support the growth of Colorado’s more than 720 bioscience companies. Names and biographies of the full board of directors are available on the CBSA website.
About the Colorado BioScience Association
Colorado BioScience Association champions life science. We serve as the hub of Colorado’s thriving bioscience sector by connecting innovators to funding, infrastructure, research and talent. From promising young companies to established corporations and institutions, we provide opportunities for networking, education and professional development. We grow the bioscience workforce and lead business expansion policies to advance the industry in our state. CBSA represents more than 350 member organizations, including biotechnology, pharmaceutical, medical device, diagnostic, ag bio and mobile digital health companies, research and academic institutions and service providers. Learn more about us at http://www.cobioscience.com.